Exome Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Exome Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Sell	50,166 -25,318	-34%	-$111K	0.15%	52
2026 Q1	$340K	Hold	75,484	–	–	0.18%	54
2025 Q4	$363K	Hold	75,484	–	–	0.17%	59
2025 Q3	$343K	Hold	75,484	–	–	0.21%	62
2025 Q2	$233K	Buy	+75,484	New	+$251K	0.17%	60
2025 Q1	–	Sell	-28,300	Closed	-$92.5K	–	60
2024 Q4	$92.5K	Buy	+28,300	New	+$104K	0.07%	59

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Exome Asset Management's ABUS Position: Q2 2026 in Review

Exome Asset Management reduced its Arbutus Biopharma (ABUS) stake by 34% in Q2 2026, selling an estimated $111K and leaving 50,166 shares worth $241K. The position accounts for 0.15% of the portfolio, ranked #52.

Exome Asset Management first reported a position in ABUS in Q4 2024 and has held it in 6 quarters since. The position peaked at $363K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Exome Asset Management held 50,166 shares of Arbutus Biopharma worth $241K as of Q2 2026.
Exome Asset Management sold 25,318 Arbutus Biopharma shares in Q2 2026, an estimated $111K.
Arbutus Biopharma made up 0.15% of Exome Asset Management's portfolio in Q2 2026, its #52 holding.
Exome Asset Management first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 6 quarters since.
Exome Asset Management's Arbutus Biopharma position peaked at $363K in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.